Expanding Our Oncology Portfolio: Announcing a Strategic agreement with ELPEN at CPHI Milan!
We are thrilled to announce that ADCAN Pharma has taken a significant step forward in our mission to provide high-quality pharmaceutical solutions. During the recent CPHI Milan which is taking place between 6th to 8th of this month and in the presence of EDE, we officially signed an agreement for a licensing agreement with ELPEN, the leading pharmaceutical company from Greece. This partnership will focus on expanding our Oncology therapy area.
“This agreement with ELPEN is a testament to ADCAN Pharma’s dedication to addressing critical unmet needs in Oncology, which fully aligns with UAE and Greece connected ties and strategic partnerships between the two countries. By partnering with an industry leader like ELPEN, we are not only expanding our product portfolio but also reinforcing our commitment to delivering impactful healthcare solutions. We are excited about the potential this collaboration holds for patients and the medical community.” Dr Fokion Sinis, CEO of ADCAN Pharma
“Our partnership with ADCAN supports the UAE’s ambition to produce its most critical medicines locally. We will begin by supplying oncology products, and in a second phase we will transfer the manufacturing technology to the UAE. ELPEN which is present in more than 90 countries worldwide, brings six decades of manufacturing expertise, and uncompromising quality standards to this effort, together with a dynamic and trusted partner in ADCAN” Mr Lefteris Tryfon, Member of the Board of Directors and COO, ELPEN
“At ELPEN MEA, patients come first, and localization is how we deliver on that commitment. This partnership opens the door to manufacturing oncology and other critical medicines here in the UAE, closer to the patients who depend on them, while strengthening the nation’s healthcare security and self-sufficiency. We are proud to contribute to the UAE’s national healthcare vision, and to do so alongside ADCAN” Dr Mohammad Allakany, ELPEN MEA General Manager
This collaboration marks another milestone in our commitment to bringing innovative and effective treatments to patients. We look forward to a fruitful partnership with ELPEN as we work together to advance cancer care.
